US FDA To Generic Sponsors: Don't Call Us, We'll GDUFA You
Executive Summary
FDA says there are only a few situations where the ANDA status call to the project manager is necessary, and industry seems to agree that review system improvements make the once-contentious check-in process less necessary.
You may also be interested in...
Goal Date Confusion: The Downside Of Generic Drug Assessment Transparency
ANDA sponsors worry launch plans cannot be finalized if US FDA will not inform them whether their application requires a facility inspection.
Goal Date Confusion: The Downside Of Generic Drug Assessment Transparency
ANDA sponsors worry launch plans cannot be finalized if US FDA will not inform them whether their application requires a facility inspection.
Outlook For Orange Book Update Not Too Rosy
With about 20,000 products eligible for US marketing status report on drugs in Orange Book, there is no timeline for all changes to be made.